Mayne Pharma Group (MYX.AX) Stock Price

Mayne Pharma Group Price

ASX·CLOSED
3.20AUD-0.04 (-1.24 %)
Market closed

Revenue has compounded at 58.8% per year over the past 18 years to 413.01 M AUD. Earnings per share have grown at 39.7% per year over the last 13 years. Mayne Pharma Group's net margin stands at -22.7%, up from -51.9% several years earlier. Mayne Pharma Group currently offers a dividend yield of about 24.29%. The payout ratio is around 38% of earnings. The dividend has grown at 28.9% per year over the past 13 years. Analysts set a median price target of 6.22 AUD, implying 94.4% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus. The stock trades about 50% above its 52-week low.

Mayne Pharma Group stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Mayne Pharma Group over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Mayne Pharma Group stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Mayne Pharma Group's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Mayne Pharma Group Stock Price History
DateMayne Pharma Group Price
8/14/20263.20 AUD
8/13/20263.24 AUD
8/12/20263.27 AUD
8/11/20263.26 AUD
8/10/20263.18 AUD
8/7/20263.15 AUD
8/6/20263.14 AUD
8/5/20263.13 AUD
8/4/20263.05 AUD
8/3/20262.92 AUD
7/31/20262.66 AUD
7/30/20262.60 AUD
7/29/20262.64 AUD
7/28/20262.62 AUD
7/27/20262.65 AUD
7/24/20262.71 AUD
7/23/20262.73 AUD
7/22/20262.77 AUD
7/21/20262.75 AUD
7/20/20262.86 AUD
7/17/20262.88 AUD
7/16/20262.92 AUD
7/15/20262.82 AUD
7/14/20262.82 AUD
7/13/20262.86 AUD
7/10/20262.87 AUD
7/9/20262.84 AUD
7/8/20262.86 AUD
7/7/20262.88 AUD
7/6/20262.79 AUD
7/3/20262.76 AUD
7/2/20262.78 AUD
7/1/20262.93 AUD
6/30/20262.76 AUD
6/29/20262.58 AUD
6/26/20262.44 AUD
6/25/20262.40 AUD
6/24/20262.38 AUD
6/23/20262.33 AUD
6/22/20262.36 AUD
6/19/20262.34 AUD
6/18/20262.36 AUD
6/17/20262.34 AUD
6/16/20262.35 AUD
6/15/20262.35 AUD
6/12/20262.41 AUD
6/11/20262.46 AUD
6/10/20262.41 AUD
6/9/20262.40 AUD
6/5/20262.30 AUD
6/4/20262.21 AUD
6/3/20262.25 AUD
6/2/20262.25 AUD
6/1/20262.33 AUD
5/29/20262.40 AUD
5/28/20262.48 AUD
5/27/20262.44 AUD
5/26/20262.34 AUD
5/25/20262.38 AUD
5/22/20262.43 AUD
5/21/20262.36 AUD
5/20/20262.29 AUD
5/19/20262.28 AUD
5/18/20262.32 AUD
5/15/20262.31 AUD
5/14/20262.28 AUD
5/13/20262.34 AUD
5/12/20262.40 AUD
5/11/20262.51 AUD
5/8/20262.58 AUD
5/7/20262.60 AUD
5/6/20262.62 AUD
5/5/20262.67 AUD
5/4/20262.81 AUD
5/1/20262.78 AUD
4/30/20262.84 AUD
4/29/20262.87 AUD
4/28/20262.69 AUD
4/27/20262.63 AUD
4/24/20262.57 AUD
4/23/20262.59 AUD
4/22/20262.55 AUD
4/21/20262.63 AUD
4/20/20262.51 AUD
4/17/20262.51 AUD
4/16/20262.42 AUD
4/15/20262.45 AUD
4/14/20262.37 AUD
4/13/20262.28 AUD
4/10/20262.24 AUD
4/9/20262.16 AUD
4/8/20262.31 AUD
4/7/20262.31 AUD
4/2/20262.33 AUD
4/1/20262.40 AUD
3/31/20262.27 AUD
3/30/20262.35 AUD
3/27/20262.28 AUD
3/26/20262.29 AUD
3/25/20262.32 AUD
3/24/20262.25 AUD
3/23/20262.22 AUD
3/20/20262.20 AUD
3/19/20262.13 AUD
3/18/20262.32 AUD
3/17/20262.40 AUD
3/16/20262.32 AUD
3/13/20262.38 AUD
3/12/20262.40 AUD
3/11/20262.65 AUD
3/10/20262.47 AUD
3/9/20262.34 AUD
3/6/20262.54 AUD
3/5/20262.48 AUD
3/4/20262.39 AUD
3/3/20262.40 AUD
3/2/20262.45 AUD
2/27/20262.52 AUD
2/26/20262.53 AUD
2/25/20262.55 AUD
2/24/20262.54 AUD
2/23/20262.61 AUD
2/20/20262.65 AUD
2/19/20262.65 AUD
2/18/20262.64 AUD
2/17/20262.65 AUD
2/16/20262.71 AUD
2/13/20262.62 AUD
2/12/20262.67 AUD
2/11/20262.95 AUD
2/10/20262.84 AUD
2/9/20262.82 AUD
2/6/20262.63 AUD
2/5/20262.70 AUD
2/4/20262.73 AUD
2/3/20262.69 AUD
2/2/20262.69 AUD
1/30/20262.80 AUD
1/29/20262.80 AUD
1/28/20262.80 AUD
1/27/20262.83 AUD
1/23/20262.90 AUD
1/22/20262.93 AUD
1/21/20262.89 AUD
1/20/20262.89 AUD
1/19/20262.89 AUD
1/16/20262.84 AUD
1/15/20262.90 AUD
1/14/20262.94 AUD
1/13/20263.01 AUD
1/12/20263.15 AUD
1/9/20263.17 AUD
1/8/20263.13 AUD
1/7/20263.20 AUD
1/6/20263.14 AUD
1/5/20263.24 AUD
1/2/20263.19 AUD
12/31/20253.11 AUD
12/30/20253.10 AUD
12/29/20253.16 AUD
12/24/20253.13 AUD
12/23/20253.00 AUD
12/22/20253.07 AUD
12/19/20253.12 AUD
12/18/20253.03 AUD
12/17/20253.04 AUD
12/16/20253.17 AUD
12/15/20253.21 AUD
12/12/20253.25 AUD
12/11/20253.19 AUD
12/10/20253.22 AUD
12/9/20253.20 AUD
12/8/20253.20 AUD
12/5/20253.21 AUD
12/4/20253.28 AUD
12/3/20253.36 AUD
12/2/20253.41 AUD
12/1/20253.65 AUD
11/28/20253.71 AUD
11/27/20253.69 AUD
11/26/20253.67 AUD
11/25/20253.66 AUD
11/24/20253.65 AUD
11/21/20254.45 AUD
11/20/20255.79 AUD
11/19/20254.79 AUD
11/18/20254.86 AUD
11/17/20254.85 AUD
11/14/20254.85 AUD
11/13/20254.85 AUD
11/12/20254.70 AUD
11/11/20254.62 AUD
11/10/20254.61 AUD
11/7/20254.90 AUD
11/6/20255.05 AUD
11/5/20254.85 AUD
11/4/20254.58 AUD
11/3/20254.57 AUD
10/31/20254.25 AUD
10/30/20256.20 AUD
10/29/20256.20 AUD
10/28/20256.08 AUD
10/27/20256.11 AUD
10/24/20256.17 AUD
10/23/20256.12 AUD
10/22/20256.20 AUD
10/21/20256.30 AUD
10/20/20256.01 AUD
10/17/20256.19 AUD
10/16/20256.30 AUD
10/15/20255.66 AUD
10/14/20255.53 AUD
10/13/20255.60 AUD
10/10/20255.85 AUD
10/9/20255.81 AUD
10/8/20255.71 AUD
10/7/20255.84 AUD
10/6/20255.64 AUD
10/3/20255.77 AUD
10/2/20255.70 AUD
10/1/20255.67 AUD
9/30/20255.15 AUD
9/29/20255.12 AUD
9/26/20255.16 AUD
9/25/20255.13 AUD
9/24/20255.00 AUD
9/23/20255.09 AUD
9/22/20254.77 AUD
9/19/20254.90 AUD
9/18/20254.98 AUD
9/17/20254.83 AUD
9/16/20254.50 AUD
9/15/20254.48 AUD
9/12/20254.53 AUD
9/11/20254.53 AUD
9/10/20254.50 AUD
9/9/20254.60 AUD
9/8/20254.50 AUD
9/5/20255.28 AUD
9/4/20255.27 AUD
9/3/20255.27 AUD
9/2/20255.19 AUD
9/1/20255.20 AUD
8/29/20255.17 AUD
8/28/20255.03 AUD
8/27/20255.20 AUD
8/26/20255.12 AUD
8/25/20255.04 AUD
8/22/20255.05 AUD
8/21/20255.13 AUD
8/20/20255.07 AUD
8/19/20255.18 AUD
8/18/20255.15 AUD
Access this data via the Eulerpool API
Get Free API Key

Mayne Pharma Group Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
401.47 M AUD
20.55 M AUD
-208.42 M AUD
Jan 1, 2022
157.61 M AUD
-55.87 M AUD
-281.29 M AUD
Jan 1, 2023
190.31 M AUD
-165.45 M AUD
117.25 M AUD
Jan 1, 2024
395.47 M AUD
-155.30 M AUD
-174.23 M AUD
Jan 1, 2025
413.01 M AUD
-71.93 M AUD
-93.84 M AUD
Jan 1, 2026 (e)
399.60 M AUD
-240.55 M AUD
-37.71 M AUD
Jan 1, 2027 (e)
400.80 M AUD
-241.28 M AUD
-28.21 M AUD
Jan 1, 2028 (e)
410.80 M AUD
-247.30 M AUD
-18.32 M AUD

Mayne Pharma Group Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 17, 2026, 1:10 AM
 
REVENUEM AUD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM AUD
EBITM AUD
EBIT MARGIN%
NET INCOMEM AUD
NET INCOME GROWTH%
DIV.AUD
DIV. GROWTH%
SHARESM
20132014201520162017201820192020202120222023202420252026e2027e2028e
84.00143.00141.00267.00572.00530.00526.00457.00401.00157.00190.00395.00413.00399.00400.00410.00
61.5470.24-1.4089.36114.23-7.34-0.75-13.12-12.25-60.8521.02107.894.56-3.390.252.50
46.4352.4556.0363.6756.8253.5860.0846.3945.3947.7747.3756.9661.0261.0261.0261.02
39.0075.0079.00170.00325.00284.00316.00212.00182.0075.0090.00225.00252.00243.46244.07250.17
11.0029.0019.0058.00129.0062.0052.004.0020.00-55.00-165.00-155.00-71.00-240.00-241.00-247.00
13.1020.2813.4821.7222.5511.709.890.884.99-35.03-86.84-39.24-17.19-60.15-60.25-60.24
-2.0021.007.0037.0088.00-133.00-279.00-92.00-208.00-281.00117.00-174.00-93.00-37.00-28.00-18.00
-133.33-1,150.00-66.67428.57137.84-251.14109.77-67.03126.0935.10-141.64-248.72-46.55-60.22-24.32-35.71
–––––––––––––0.430.430.43
––––––––––––––––
443.30645.60715.45858.0073.0273.1473.7576.4778.5882.3082.1879.6279.1479.1479.1479.14
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Mayne Pharma Group generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Mayne Pharma Group retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Mayne Pharma Group's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Mayne Pharma Group has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Mayne Pharma Group's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Mayne Pharma Group stock margins

The Mayne Pharma Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Mayne Pharma Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Mayne Pharma Group.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
45.50 %
5.12 %
-51.92 %
Jan 1, 2022
47.74 %
-35.45 %
-178.47 %
Jan 1, 2023
47.51 %
-86.94 %
61.61 %
Jan 1, 2024
57.11 %
-39.27 %
-44.06 %
Jan 1, 2025
61.06 %
-17.41 %
-22.72 %
Jan 1, 2026 (e)
61.06 %
-60.20 %
-9.44 %
Jan 1, 2027 (e)
61.06 %
-60.20 %
-7.04 %
Jan 1, 2028 (e)
61.06 %
-60.20 %
-4.46 %

Mayne Pharma Group Stock Revenue, EBIT, Earnings per Share

The Mayne Pharma Group earnings per share therefore indicates how much revenue Mayne Pharma Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
5.11 AUD
0.26 AUD
-2.65 AUD
Jan 1, 2022
1.92 AUD
-0.68 AUD
-3.42 AUD
Jan 1, 2023
2.32 AUD
-2.01 AUD
1.43 AUD
Jan 1, 2024
4.97 AUD
-1.95 AUD
-2.19 AUD
Jan 1, 2025
5.22 AUD
-0.91 AUD
-1.19 AUD
Jan 1, 2026 (e)
5.05 AUD
-3.04 AUD
-0.48 AUD
Jan 1, 2027 (e)
5.06 AUD
-3.05 AUD
-0.36 AUD
Jan 1, 2028 (e)
5.19 AUD
-3.12 AUD
-0.23 AUD

Mayne Pharma Group business model & stock analysis

Mayne Pharma Group Ltd. is a leading company in the field of pharmaceutical development and production with manufacturing facilities in Australia and the USA. The company is headquartered in Sydney, Australia and employs over 1,100 employees worldwide. The history of Mayne Pharma dates back to 1845 when the company was founded as a manufacturer of herbal medicine. Over the years, the company has evolved and focused on the pharmaceutical industry, eventually being renamed Mayne Nickless Ltd in 1981. In 2000, the company established its subsidiary Mayne Pharma, specializing in the development and production of generic drugs. Through the acquisition of other companies, Mayne Pharma has expanded its product range and expanded into the USA in 2007. Mayne Pharma focuses on the production of generics and specialty pharmaceuticals, which are marketed worldwide through a variety of distribution channels. The company invests heavily in research and development to develop new products and improve existing ones. The goal is to continuously expand the offering and increase market presence. Through the expansion of the product portfolio and the exploration of new markets, Mayne Pharma has gained a strong position in the pharmaceutical industry in recent years. Mayne Pharma is divided into three divisions: generics, specialty pharmaceuticals, and beauty products. The generics division includes a wide range of prescription generic drugs marketed in the USA, Australia, Canada, and other countries. The company is able to produce cost-effective medications to provide affordable drugs to patients worldwide. The specialty pharmaceuticals division focuses on medications for the treatment of diseases such as cancer, pain, and cardiovascular diseases. Mayne Pharma aims to improve treatment outcomes for patients in these areas and has a promising product development pipeline that includes many innovative therapy options. The beauty products division offers a wide range of high-quality skincare products sold worldwide. This includes skin creams, lip care products, and sunscreens. This division is growing steadily and offers great potential, as it operates not only in the healthcare sector but also in the beauty market. Mayne Pharma has a wide range of products, ranging from medications for everyday ailments to life-saving specialty preparations. Key products include: - Doryx: An oral antibiotic therapy for the treatment of mild to moderate acne. - Lonsurf: A cancer-fighting medication that extends the survival time of advanced colorectal cancer patients. - Kapanol: A long-acting opioid for pain relief in patients with severe pain. - Tolsura: An easy-to-use medication for the treatment of fungal infections, particularly suitable for patients who have difficulty swallowing tablets. - Zenavod: A topical medication for the treatment of vaginal infections. - Golden Glow Sunscreen: A high-quality sunscreen with SPF 50+ that prevents skin irritation and sunburn. In conclusion, Mayne Pharma is a proven and innovative company that focuses on the development and production of generics and specialty pharmaceuticals. With its extensive product range and business activities in key international markets, Mayne Pharma has an outstanding reputation in the pharmaceutical industry.

Mayne Pharma Group SWOT Analysis

Strengths

Mayne Pharma Group Ltd possesses several strengths that contribute to its competitive advantage in the pharmaceutical industry. Firstly, it has a robust portfolio of products, including both branded and generic drugs, which caters to a diverse range of therapeutic areas. This broad offering strengthens the company's market positioning and allows for revenue diversification.

Secondly, Mayne Pharma has a strong research and development division, enabling them to develop innovative formulations and improve existing products. This capability enhances their ability to meet evolving customer needs and differentiate themselves in the market.

Thirdly, the company has a global presence, with a solid footprint in various markets. This international reach provides Mayne Pharma with opportunities for revenue growth, market expansion, and potential partnerships.

Weaknesses

Despite its strengths, Mayne Pharma also faces a few weaknesses that need to be addressed. Firstly, the company heavily relies on a few key products for a significant portion of its revenue. This concentration poses risks, as any decline in sales or competition in those specific products could impact overall financial performance.

Secondly, Mayne Pharma's manufacturing capabilities have faced quality issues in the past, resulting in regulatory actions. These incidents have the potential to harm the company's reputation and increase compliance costs.

Lastly, compared to some larger competitors, Mayne Pharma has relatively limited financial resources. This could limit their ability to invest in research and development or pursue strategic acquisitions to expand their product portfolio.

Opportunities

Mayne Pharma operates in an industry with several growth opportunities. Firstly, the increasing global demand for pharmaceutical products, driven by an aging population and rising healthcare needs, presents a favorable market environment for the company to expand its sales.

Secondly, the growing trend towards specialty pharmaceuticals and personalized medicine opens up avenues for Mayne Pharma to develop targeted therapies and establish themselves as a leader in specific disease areas.

Moreover, the company can explore partnerships or licensing agreements with research institutions or other pharmaceutical firms to leverage their expertise and enhance their product pipeline.

Threats

Mayne Pharma faces various threats that could impact its performance. Firstly, intense competition within the pharmaceutical industry can limit market share and pricing power, potentially leading to reduced profitability. The presence of both domestic and international competitors further intensifies this rivalry.

Secondly, regulatory changes or stricter enforcement could increase compliance costs and add complexities to the approval process for new products or manufacturing facilities.

Lastly, macroeconomic factors, such as fluctuations in exchange rates or changes in government healthcare policies, may affect the affordability and accessibility of pharmaceutical products, potentially impacting Mayne Pharma's sales and profitability.

Mayne Pharma Group Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Mayne Pharma Group historical P/E ratio, EBIT multiple, and P/S ratio

Mayne Pharma Group annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Mayne Pharma Group shares outstanding

The number of shares of Mayne Pharma Group was 79.14 M in 2025. This indicates how many shares Mayne Pharma Group is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
78.58 M Stocks
Jan 1, 2022
82.30 M Stocks
Jan 1, 2023
82.18 M Stocks
Jan 1, 2024
79.62 M Stocks
Jan 1, 2025
79.14 M Stocks
Jan 1, 2026 (e)
79.14 M Stocks
Jan 1, 2027 (e)
79.14 M Stocks
Jan 1, 2028 (e)
79.14 M Stocks

Mayne Pharma Group stock splits

In Mayne Pharma Group's history, there have been no stock splits.

Mayne Pharma Group Dividend History

3 years of dividend payments

YearAnnual DividendYoY ChangePayments
20230.78AUD↑ 5,340.0%1×
20110.01AUD↓ 50.0%1×
20100.03AUD—1×

Mayne Pharma Group dividend payout ratio

In 2025, Mayne Pharma Group had a payout ratio of 88.23%. The payout ratio indicates the percentage of the company's profits that Mayne Pharma Group distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
148.75 %
Jan 1, 2022
123.02 %
Jan 1, 2023
38.31 %
Jan 1, 2024
103.36 %
Jan 1, 2025
88.23 %
Jan 1, 2026 (e)
76.63 %
Jan 1, 2027 (e)
89.41 %
Jan 1, 2028 (e)
84.76 %

Current Mayne Pharma Group forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
80.00 % (4)
Hold
20.00 % (1)
Sell
0.00 % (0)
12M Price Target
6.22
Last Price
3.20
Currency
AUD
12M Return Potential
94.44 %
LTM Return
0 %

Mayne Pharma Group Earnings Calls

Mayne Pharma Group Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
2/22/2024-0.51AUD-155.14 MAUD-2024 Q2
8/23/2023-0.01AUD-214.88 MAUD-2023 Q4
2/22/2023-0.01AUD-242.69 MAUD-2023 Q2
8/26/2022-0.01AUD-238.52 MAUD-2022 Q4
8/27/2021-0.03AUD-209.29 MAUD-2021 Q4
2/24/2021-0.40AUD-204.52 MAUD-2021 Q2

EESG©

Eulerpool ESG Scorecard© for the Mayne Pharma Group stock

52/100
32
Environment
99
Social
26
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees51
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Mayne Pharma Group shareholder structure

% Name
5.50478%
Rubric Capital Management LP
Rubric Capital Management LP
5.10485%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
2.91169%
RQI Investors
RQI Investors
1.77797%
Goldman Sachs Financial Markets Pty. Ltd.
Goldman Sachs Financial Markets Pty. Ltd.
1.63185%
Vanguard Investments Australia Ltd.
Vanguard Investments Australia Ltd.
1.20857%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.

Mayne Pharma Group Beneficial Ownership Filings (SEC 13D/G)

Free Float
85.5%
Float Shares
-
Shares Outstanding
-

Mayne Pharma Group Executives and Management Board

10 members · avg. age 63 · 40 % women

SB

Mr. Shawn O' Brien (65)

Chief Executive Officer, Managing Director, Executive Director · since 2022

2.06 M AUD

Management

AG

Mr. Aaron Gray

Chief Financial Officer

1.31 M AUD
LL

Ms. Laura Loftus

Company Secretary

–

Board of Directors

FC

Mr. Frank Condella (70)

Non-Executive Independent Chairman of the Board

305,398.00 AUD
AC

Ms. Ann Custin (64)

Independent Non-Executive Director

235,157.00 AUD
PR

Prof. Bruce Robinson (68)

Independent Non-Executive Director

219,385.00 AUD
PB

Mr. Patrick Blake (61)

Independent Non-Executive Director

218,360.00 AUD
DP

Mr. David Petrie

Non-Executive Director

217,862.00 AUD
KM

Dr. Kathryn Macfarlane (59)

Independent Non-Executive Director

215,835.00 AUD

Mayne Pharma Group Supply Chain

Mayne Pharma Group Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
7 companies
#NameTrend
1
X4 Pharmaceuticals
Supplier·Customer·Biotechnology·US
0.10
-0.74
-0.83
0.39
0.82
0.75
2
SAWAI GROUP HOLDINGS
Supplier·Customer·Pharmaceuticals·JP
-0.62
-0.70
-0.39
0.22
0.58
0.70
3
Mithra Pharmaceuticals
Supplier·Customer·Pharmaceuticals·BE
0.71
-0.71
-0.18
0.33
0.58
0.41
#NameTrend
1
Teligent
Supplier·Customer·Pharmaceuticals·US
0.66
-0.26
-0.15
0.60
—
—
2
HSBC Holdings
Supplier·Customer·Banks·GB
0.83
-0.03
0.62
-0.27
-0.50
-0.47
3
JPMorgan Chase
Supplier·Customer·Banks·US
0.48
-0.41
0.01
0.54
0.58
-0.29
4
Citigroup
Supplier·Customer·Banks·US
0.36
0.26
0.03
0.44
0.72
0.03

Frequently asked questions about Mayne Pharma Group

Mayne Pharma Group Ltd operates as a pharmaceutical company. Its business model revolves around developing, manufacturing, and distributing branded and generic prescription pharmaceuticals. Mayne Pharma specializes in providing contract development and manufacturing services to customers worldwide. By leveraging its expertise, capabilities, and global reach, Mayne Pharma aims to provide cost-effective and high-quality pharmaceutical products. The company focuses on various therapeutic areas, including cardiology, oncology, women's health, dermatology, and specialty products, catering to the needs of patients and healthcare professionals. Mayne Pharma Group Ltd strives to deliver innovative healthcare solutions and improve patient outcomes through its comprehensive business model.

Mayne Pharma Group Ltd is primarily active in the pharmaceutical industry.

The main competitors of Mayne Pharma Group Ltd in the market include companies like Teva Pharmaceutical Industries Ltd, Fagron NV, and Bio-Pharmaceutics, Inc. These companies operate in the pharmaceutical industry, focusing on generic drugs and specialty pharmaceuticals, similar to Mayne Pharma Group Ltd. By constantly monitoring and analyzing competition, Mayne Pharma Group Ltd strives to maintain its position and market share through strategic business decisions and product innovations.

Mayne Pharma Group Ltd is an Australian pharmaceutical company with a rich history and background. Founded in 1845 as FH Faulding & Co, it has established itself as a reputable player in the industry. In 2015, the company acquired the generic products division of a large U.S. pharmaceutical company, strengthening its global presence. Mayne Pharma Group Ltd specializes in the development and manufacture of generic and specialty pharmaceutical products, focusing on areas such as oncology, dermatology, and women's health. With a commitment to quality and innovation, Mayne Pharma Group Ltd continues to make significant contributions to the healthcare sector globally.

Mayne Pharma Group Ltd has achieved significant milestones in its journey. Some notable accomplishments include the acquisition of Metrics Contract Services, a contract development and manufacturing organization. This strategic move expanded the company's capability to offer a full-service platform for pharmaceutical development and manufacturing. Mayne Pharma also received FDA approval for various generic and specialty pharmaceutical products, further strengthening its market presence in the United States. Additionally, the company successfully launched new products, such as Doryx, in the dermatology segment, and secured international distribution agreements. Mayne Pharma Group Ltd continues to strive for innovative solutions in the pharmaceutical industry to enhance shareholder value and meet patient needs.

Mayne Pharma Group Ltd primarily operates in various countries and regions around the world. The company has a strong presence in Australia, where it is headquartered, and it also has a significant presence in the United States. With a focus on developing, manufacturing, and marketing branded and generic pharmaceutical products, Mayne Pharma Group Ltd serves customers and healthcare professionals in these key markets. Additionally, the company's global reach extends to other regions, including Europe and Asia, where it actively pursues business opportunities and fosters growth. Mayne Pharma Group Ltd's international presence underscores its commitment to delivering high-quality healthcare solutions to a diverse range of patients globally.

Mayne Pharma Group Ltd is a pharmaceutical company that values innovation, integrity, and patient care. With a commitment to developing high-quality, affordable medications, Mayne Pharma Group Ltd aims to improve the health and well-being of individuals worldwide. The company's corporate philosophy revolves around delivering effective solutions through research, development, and manufacturing of pharmaceutical products. Mayne Pharma Group Ltd prioritizes transparency, ethical practices, and collaboration in its operations, ensuring compliance with regulatory standards. By focusing on customer needs and advancing pharmaceutical technologies, Mayne Pharma Group Ltd continues to build a reputation as a trusted and forward-thinking healthcare organization.

Analysts currently set an average price target of 6.22 AUD for the Mayne Pharma Group stock (median: 6.22 AUD), implying +94.4 % versus the latest price. The consensus is based on 5 analyst ratings.

Mayne Pharma Group Analyst Price Targets 2026

5 analysts currently rate the Mayne Pharma Group stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Mayne Pharma Group to generate revenue of 399.60 M AUD and earnings per share of -0.48 AUD.

Mayne Pharma Group Analyst Price Targets 2026

Converted at the current exchange rate, the Mayne Pharma Group share trades at 1.96 EUR (3.20 AUD).

The Mayne Pharma Group share (MYX.AX) is listed on 5 stock exchanges, including: Frankfurt (HG6.F), Düsseldorf (HG6.DU), Hamburg (HG6.HM), ASX (MYX.AX).

Mayne Pharma Group Ltd is an Australian pharmaceutical company headquartered in Salisbury, South Australia. It was founded in 2015 through the merger of Mayne Pharma Limited and Hospira Australia Pty Ltd. The company specializes in the development, manufacturing, and marketing of generic and specialized pharmaceutical products. Overall, the company operates in four main business segments: generics, specialized products, contract manufacturing, and distribution in the United States. Mayne Pharma's generics division produces a wide range of pharmaceutical products in various categories such as cardiology, gastroenterology, analgesics, and antibiotics. Mayne Pharma is also involved in the manufacture of generics with controlled release of active ingredients and long-acting generics. Mayne Pharma's specialized products are medicines used to treat rare or chronic diseases and often have higher added value than standard generics. This includes products in the fields of dermatology, oncology, endocrinology, urology, and psychiatry. Mayne Pharma also operates contract manufacturing, using its own infrastructure to manufacture products on behalf of third parties. Mayne Pharma's contract manufacturing offers both small and large molecule products. This option allows companies to manufacture their own products without having to build their own production and development system. In the United States, Mayne Pharma is involved in the distribution of pharmaceutical products and operates a distribution channel in the industry. This expands Mayne Pharma's portfolio with commercially attractive and acquired active ingredients and excipients. Mayne Pharma has a strong portfolio of products and assets to make it a leading provider of generic and specialized pharmaceuticals. The company also has a solid pipeline of compounds in various stages to support future growth. Mayne Pharma's success is based on a combination of high quality standards, competitive prices, a strong pipeline portfolio, and a dedicated strategic partnership with other companies in the industry. Mayne Pharma is focused on providing its customers with high quality and affordable medications and strengthening its leadership position in global markets.

The expected revenue of Mayne Pharma Group is 399.60 M AUD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Mayne Pharma Group is -37.71 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Mayne Pharma Group is currently -6.72. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Mayne Pharma Group stock.

The price-to-sales ratio (P/S) of Mayne Pharma Group is currently 0.63. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Mayne Pharma Group stock.

The Eulerpool Quality Score for Mayne Pharma Group is 3/10.

The ISIN of Mayne Pharma Group is AU000000MYX0. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Mayne Pharma Group is A1C821. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Mayne Pharma Group is MYX.AX. The ticker symbol is used to trade Mayne Pharma Group shares on the stock exchange.

Over the past 12 months, Mayne Pharma Group paid a dividend of 0.78 AUD . This corresponds to a dividend yield of about 24.29 %. For the coming 12 months, Mayne Pharma Group is expected to pay a dividend of 0.43 AUD.

The current dividend yield of Mayne Pharma Group is 24.29 %.

Mayne Pharma Group paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 0.43 AUD are expected. This corresponds to a dividend yield of 13.44 %.

Mayne Pharma Group is assigned to the 'Health' sector.

To receive the latest dividend of Mayne Pharma Group from amounting to 0.78 AUD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

The dividends of Mayne Pharma Group are distributed in AUD.

All fundamentals and in-depth analysis of Mayne Pharma Group

Our stock analysis for Mayne Pharma Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mayne Pharma Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Mayne Pharma Group Stock
Mayne Pharma Group Revenue→
Mayne Pharma Group Stock
Mayne Pharma Group Net Income→
Mayne Pharma Group Stock
Mayne Pharma Group P/E→
Mayne Pharma Group Stock
Mayne Pharma Group P/S→
Mayne Pharma Group Stock
Mayne Pharma Group EBIT→
Mayne Pharma Group Stock
Mayne Pharma Group Dividend→
Mayne Pharma Group Stock
Mayne Pharma Group Directors Dealings→
Mayne Pharma Group Stock
Mayne Pharma Group Stocks→
Mayne Pharma Group Stock
Mayne Pharma Group Market capitalization→
Mayne Pharma Group Stock
Mayne Pharma Group Debt→
Mayne Pharma Group Stock
Mayne Pharma Group Liabilities→
Mayne Pharma Group Stock
Mayne Pharma Group Equity→
Mayne Pharma Group Stock
Mayne Pharma Group AAQS→
Mayne Pharma Group Stock
Mayne Pharma Group Employees→
Mayne Pharma Group Stock
Mayne Pharma Group ROE→
Mayne Pharma Group Stock
Mayne Pharma Group ROA→
Mayne Pharma Group Stock
Mayne Pharma Group ROCE→
Mayne Pharma Group Stock
Mayne Pharma Group News→
Mayne Pharma Group Stock
Mayne Pharma Group Analyst Price Targets→

Health Stocks

Maze TherapeuticsMayinglong Pharmaceutical Group CoMBX BiosciencesMay & Baker NigeriaMcKessonMaxWin International HoldingsMdwerksMaxCyteMDxHealthMax IndiaMe TodayMax Healthcare InstituteAll Stocks A–Z →